Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...
Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...
A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...
The Healthy @Reader's Digest on MSN
Cleveland Clinic cardiologist: A new cholesterol value is being checked for the first time ever in the US
It's called the Lp(a) cholesterol test. Leslie Cho, MD explains what the changed recommendation means.
The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), ...
Founded in 1946, White Wilson has nine clinic locations across Fort Walton Beach, Crestview, DeFuniak Springs, Destin, Navarre, and Niceville; The practice includes more than 70 p ...
Indian American interventional cardiologist is recognized nationally for his leadership in radial-artery catheterization.
Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten experienced reduced obstruction, allowing blood to ...
New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...
Mavacamten has been approved for adults with hypertrophic cardiomyopathy since 2022, but hadn’t yet been tested in ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
Vall d’Hebron reorganized care into Knowledge Areas; the Heart Area pilot cut length of stay by 18%, 30-day readmissions by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results